Wed, Aug 20, 2014, 12:58 AM EDT - U.S. Markets open in 8 hrs 32 mins

Recent

% | $
Quotes you view appear here for quick access.

Bone Care International (BCII) Message Board

  • bfg93105 bfg93105 Jun 22, 1999 7:31 PM Flag

    BCII has not defined it's

    trading channel yet. Come to our free stock trading club,BBS,chat room(9pm ET) with traders to answer questions,basic ed website and more at: http://maxpages.com/zorro/Home

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Take a look at Cist: Their book value is almost
      2x their market cap... they own the patents on IL1b
      and have a
      potential 30 million dollar vaccine
      deal.

      Cistron One of First Biotechnology Companies to
      Use
      Internet to Merge or Sell Or to License Its
      Technology

      PINE BROOK, N.J., June 23 /PRNewswire/ -- One of
      the first attempts on the Internet to sell a
      publicly
      traded biotechnology
      company has been made by
      Cistron Biotechnology, Inc.'s (OTC: CIST - news)
      investment banker,
      Genome Securities, Inc. at

      http://www.genomesecurities.com.

      On the web site, Cistron is offered as a business
      available for sale, merger or acquisition. Another
      option
      provides for the
      licensing of Cistron's
      intellectual property rights by other companies. Genome
      Securities expects to receive
      proposals between
      now
      and August 31.

      The web site shows Cistron as
      having a strong cash position and owning the
      intellectual property rights to
      Interleukin 1 (IL-lb),

      a monoclonal antibody with potential in the
      treatment of rheumatoid arthritis and other therapeutic

      applications. The
      biotechnology company is also a partner
      with Pasteur Merieux Connaught in determining the use
      of IL-lb
      in vaccine adjuvants,
      a
      relationship that could yield $31 million to Cistron in
      milestone payments and royalties.

      Robert W.
      Naismith, Genome Securities' CEO stated, ``It is apparent
      that small cap companies require
      innovation in

      developing interest in their technology. Electronic commerce
      allows an entirely new marketing paradigm
      and
      distribution
      opportunity. In an attempt to maximize the value
      of Cistron's technology and to provide for the
      widest
      possible exposure, we
      are proffering the
      company on the Internet. We plan on following this with
      targeted e-mail inviting the life
      science company

      business development professionals to visit our website to
      review the opportunity.''

      SOURCE: Cistron
      Biotechnology, Inc.

 

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.